

# François Bertucci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2469783/publications.pdf>

Version: 2024-02-01

126  
papers

5,051  
citations

87843

38  
h-index

106281

65  
g-index

131  
all docs

131  
docs citations

131  
times ranked

8382  
citing authors

#	ARTICLE	IF	CITATIONS
1	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. <i>Oncogene</i> , 2022, 41, 125-137.	2.6	10
2	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. <i>Npj Breast Cancer</i> , 2022, 8, 12.	2.3	6
3	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
4	BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. <i>Cell Death and Disease</i> , 2022, 13, 96.	2.7	13
5	Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. <i>Cell Research</i> , 2022, 32, 477-490.	5.7	101
6	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, 501-511.	1.9	14
7	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study. <i>Molecular Oncology</i> , 2022, 16, 2057-2070.	2.1	4
8	RE: NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1046-1047.	3.0	9
9	Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 932.	1.7	5
10	Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P1-04-07-P1-04-07.	0.4	1
11	Ketogenic HMGâ€œCoA lyase and its product Î²â€œhydroxybutyrate promote pancreatic cancer progression. <i>EMBO Journal</i> , 2022, 41, e110466.	3.5	24
12	Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease. <i>Current Oncology</i> , 2022, 29, 1683-1694.	0.9	3
13	CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response. <i>Cancers</i> , 2022, 14, 1306.	1.7	3
14	Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 655.	1.1	2
15	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial. <i>Cancers</i> , 2022, 14, 2275.	1.7	0
16	Overcoming Resistance to Antiâ€œNectin-4 Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1227-1235.	1.9	13
17	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. <i>Science China Life Sciences</i> , 2022, 65, 2205-2217.	2.3	7
18	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networksâ€™ Outcome?. <i>Cancers</i> , 2022, 14, 2620.	1.7	4

#	ARTICLE	IF	CITATIONS
19	CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression. <i>Cancers</i> , 2022, 14, 3356.	1.7	2
20	Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. <i>Cell Metabolism</i> , 2021, 33, 51-64.e9.	7.2	211
21	Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	11
22	Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2314-2325.	3.2	10
23	Case Report: Grade 2 Metastatic Pancreatic Neuroendocrine Tumor With Progression of One Metastasis After Pregnancy to Grade 3 Large-Cell Neuroendocrine Carcinoma: One Case Cured by Resection With Genomic Characterization of the Two Components. <i>Frontiers in Oncology</i> , 2021, 11, 646992.	1.3	5
24	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2021, 141, 761-769.e2.	0.3	7
25	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021, 13, 87.	3.6	24
26	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11507-11507.	0.8	15
27	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021, 21, 631.	1.1	14
28	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 48.	2.3	3
29	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSÂ© pembrolizumab study from Unicancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11520-11520.	0.8	19
30	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. <i>Cancers</i> , 2021, 13, 2807.	1.7	19
31	Antisense Oligonucleotide-Based Therapeutic against Menin for Triple-Negative Breast Cancer Treatment. <i>Biomedicines</i> , 2021, 9, 795.	1.4	5
32	WEE1 Dependency and Pejorative Prognostic Value in Tripleâ€Negative Breast Cancer. <i>Advanced Science</i> , 2021, 8, e2101030.	5.6	8
33	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. <i>Molecular Oncology</i> , 2021, 15, 2752-2765.	2.1	19
34	The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 4656.	1.7	10
35	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2021, 10, 1929724.	2.1	22
36	CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. <i>Cancers</i> , 2021, 13, 4966.	1.7	6

#	ARTICLE	IF	CITATIONS
37	TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021, 159, 205-214.	1.3	7
38	Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer. <i>In Vivo</i> , 2020, 34, 177-184.	0.6	10
39	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	2.1	23
40	Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. <i>Current Opinion in Oncology</i> , 2020, 32, 585-593.	1.1	3
41	Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer Letter. <i>Clinical Cancer Research</i> , 2020, 26, 5539-5539.	3.2	0
42	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 575978.	1.3	7
43	Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?. <i>Cancers</i> , 2020, 12, 2470.	1.7	14
44	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6254-6265.	3.2	22
45	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , 2020, 20, 430.	1.1	4
46	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
47	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. <i>Cancers</i> , 2020, 12, 1378.	1.7	29
48	New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. <i>Cancers</i> , 2020, 12, 1573.	1.7	25
49	The therapeutic response of ER+/HER2 <sup>-</sup> breast cancers differs according to the molecular Basal or Luminal subtype. <i>Npj Breast Cancer</i> , 2020, 6, 8.	2.3	27
50	Inflammatory breast cancer cells are characterized by abrogated TGF $\beta$ 1-dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 385-395.	1.1	18
51	Genomic landscape of inflammatory breast cancer identifies potential actionable genetic alterations. <i>Oncoscience</i> , 2020, 7, 57-59.	0.9	0
52	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019, 11, 1158.	1.7	6
53	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
54	Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation. <i>Clinical Epigenetics</i> , 2019, 11, 141.	1.8	11

#	ARTICLE	IF	CITATIONS
55	A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. <i>EMBO Molecular Medicine</i> , 2019, 11, e9930.	3.3	27
56	Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour. <i>Case Reports in Oncology</i> , 2019, 12, 644-649.	0.3	0
57	PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1655362.	2.1	39
58	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. <i>Cancers</i> , 2019, 11, 774.	1.7	23
59	PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. <i>Molecular Oncology</i> , 2019, 13, 1577-1588.	2.1	15
60	Genomic characterization of metastatic breast cancers. <i>Nature</i> , 2019, 569, 560-564.	13.7	448
61	XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 596.	1.0	23
62	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 612.	1.0	5
63	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. <i>Cancers</i> , 2019, 11, 665.	1.7	25
64	Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. <i>Cancers</i> , 2019, 11, 497.	1.7	61
65	ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 931-940.	2.9	13
66	Validation of Neutrophil Count as An Algorithm-Based Predictive Factor of Progression-Free Survival in Patients with Metastatic Soft Tissue Sarcomas Treated with Trabectedin. <i>Cancers</i> , 2019, 11, 432.	1.7	7
67	Outpatient Cancer Care Delivery in the Context of E-Oncology: A French Perspective on "Cancer outside the Hospital Walls". <i>Cancers</i> , 2019, 11, 219.	1.7	21
68	MARCKS protein overexpression is associated with poor prognosis in male breast cancer. <i>Cancer Biomarkers</i> , 2019, 26, 513-522.	0.8	8
69	Sensitive and easy screening for circulating tumor cells by flow cytometry. <i>JCI Insight</i> , 2019, 4, .	2.3	31
70	"Wnt/β-Catenin in GIST" Letter. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 327-328.	1.9	4
71	Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. <i>Clinical Sarcoma Research</i> , 2018, 8, 11.	2.3	6
72	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	1.7	40

#	ARTICLE	IF	CITATIONS
73	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 1383-1391.	2.9	54
74	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/ $\beta$ -Catenin Signaling. <i>Stem Cell Reports</i> , 2018, 11, 1040-1050.	2.3	18
75	Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value. <i>International Journal of Molecular Sciences</i> , 2018, 19, 41.	1.8	7
76	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018, 99, 28-36.	1.3	13
77	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. <i>Oncolmmunology</i> , 2017, 6, e1278100.	2.1	65
78	miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. <i>Cell Reports</i> , 2017, 18, 2256-2268.	2.9	111
79	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. <i>Oncolmmunology</i> , 2017, 6, e1253654.	2.1	146
80	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability. <i>Nature Medicine</i> , 2017, 23, 568-578.	15.2	131
81	Prognostic Value of Molecular Subtypes in Pancreatic Cancer. <i>Pancreas</i> , 2017, 46, e29-e31.	0.5	7
82	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 593-606.	1.1	3
83	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). <i>Neoplasia</i> , 2017, 19, 564-573.	2.3	25
84	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 28-36.	1.3	48
85	Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas Letter. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2324-2324.	1.9	2
86	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
87	A 25-gene classifier predicts overall survival in resectable pancreatic cancer. <i>BMC Medicine</i> , 2017, 15, 170.	2.3	64
88	Validation and comparison of the molecular classifications of pancreatic carcinomas. <i>Molecular Cancer</i> , 2017, 16, 168.	7.9	38
89	Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2017, 10, 66-76.	0.3	6
90	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , 2016, 58, 90-96.	1.3	111

#	ARTICLE	IF	CITATIONS
91	PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. <i>Developmental Cell</i> , 2016, 37, 311-325.	3.1	63
92	SPAG5: the ultimate marker of proliferation in early breast cancer?. <i>Lancet Oncology</i> , The, 2016, 17, 863-865.	5.1	11
93	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 600-611.	5.1	43
94	The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. <i>Oncolmmunology</i> , 2016, 5, e1085148.	2.1	45
95	Bevacizumab in HER2-negative inflammatory breast cancer. <i>Oncoscience</i> , 2016, 3, 297-298.	0.9	2
96	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016, 7, 27208-27219.	0.8	69
97	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. <i>Anticancer Research</i> , 2016, 36, 293-9.	0.5	7
98	Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 191-200.	1.0	3
99	Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 138.	1.8	38
100	High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature. <i>Clinical Sarcoma Research</i> , 2015, 5, 25.	2.3	2
101	<i>PDL1</i> expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015, 6, 13506-13519.	0.8	105
102	Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015, 51, 742-750.	1.3	86
103	Decreased expression of ABAT and STC2 hallmarks ER $\alpha$ -positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233.	2.1	64
104	The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 54.	2.2	2
105	PDL1 expression is an independent prognostic factor in localized GIST. <i>Oncolmmunology</i> , 2015, 4, e1002729.	2.1	75
106	Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. <i>PLoS ONE</i> , 2014, 9, e104302.	1.1	43
107	Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. <i>PLoS ONE</i> , 2014, 9, e81843.	1.1	53
108	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. <i>Molecular Cancer</i> , 2014, 13, 228.	7.9	91

#	ARTICLE	IF	CITATIONS
109	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. <i>Cancer Letters</i> , 2014, 355, 70-75.	3.2	44
110	ESPL1 is a candidate oncogene of luminal B breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 51-59.	1.1	51
111	Genomic profiling of inflammatory breast cancer: A review. <i>Breast</i> , 2014, 23, 538-545.	0.9	46
112	Personalized medicine: Present and future of breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 223-233.	2.0	49
113	Primary Synovial Sarcoma of the Thyroid Gland: Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2014, 7, 6-13.	0.3	19
114	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R112.	2.2	46
115	Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 4-8.	0.6	23
116	Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 156-164.	1.5	6
117	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. <i>Clinical Cancer Research</i> , 2013, 19, 4685-4696.	3.2	130
118	Genomic and expression analysis of microdissected inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 761-772.	1.1	56
119	Difference in Therapeutic Response Between Basal and Nonbasal Triple-Negative Breast Cancers. <i>Oncologist</i> , 2013, 18, 1060-1061.	1.9	3
120	Gene Expression Profiling of Solitary Fibrous Tumors. <i>PLoS ONE</i> , 2013, 8, e64497.	1.1	21
121	8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e37943.	1.1	34
122	High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. <i>PLoS ONE</i> , 2011, 6, e16950.	1.1	57
123	Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer. <i>PLoS ONE</i> , 2011, 6, e27656.	1.1	143
124	How basal are triple-negative breast cancers?. <i>International Journal of Cancer</i> , 2008, 123, 236-240.	2.3	384
125	Defining the Molecular Biology of Inflammatory Breast Cancer. <i>Seminars in Oncology</i> , 2008, 35, 41-50.	0.8	52
126	Integrated Profiling of Basal and Luminal Breast Cancers. <i>Cancer Research</i> , 2007, 67, 11565-11575.	0.4	254